No full-text available
To read the full-text of this research,
you can request a copy directly from the authors.
N,N'-Dibenzylethylenediamine Penicillin: A New Repository Form of Penicillin
Apurinic/apyrimidinic (AP) sites, 5-formyluracil (fU) and 5-formylcytosine (fC) are abundant DNA modifications that share aldehyde-type reactivity. Here, we demonstrate that polyamines featuring at least one secondary 1,2-diamine fragment in combination with aromatic units form covalent DNA adducts upon reaction with AP sites (with concomitant cleavage of the AP strand), fU and, to a lesser extent, fC residues. Using small-molecule mimics of AP site and fU, we show that reaction of secondary 1,2-diamines with AP sites leads to the formation of unprecedented 3'-tetrahydrofuro[2,3,4-ef]-1,4-diazepane ('ribodiazepane') scaffold, whereas the reaction with fU produces cationic 2,3-dihydro-1,4-diazepinium adducts via uracil ring opening. The reactivity of polyamines towards AP sites versus fU and fC can be tuned by modulating their chemical structure and pH of the reaction medium, enabling up to 20-fold chemoselectivity for AP sites with respect to fU and fC. This reaction is efficient in near-physiological conditions at low-micromolar concentration of polyamines and tolerant to the presence of a large excess of unmodified DNA. Remarkably, 3'-ribodiazepane adducts are chemically stable and resistant to the action of apurinic/apyrimidinic endonuclease 1 (APE1) and tyrosyl-DNA phosphoesterase 1 (TDP1), two DNA repair enzymes known to cleanse a variety of 3' end-blocking DNA lesions.
Understanding how the biological environment contributes to drug release following administration is increasingly becoming a focus for drug delivery research. Achieving therapeutic levels of a bioactive relies on appropriate drug release following parenteral administration that must be complimentary to subsequent drug absorption, distribution, metabolism and elimination. The biological characteristics of the injection site can have an influence on the drug absorption process. In this chapter the intravenous, intramuscular and subcutaneous routes for parenteral administration of extended release products will be discussed.
Benzathine is prepared in good yields from cyanobenzene by a combination of electrochemical hydrogenation and Kolbe electrolysis using nickel and platinum electrodes in the presence of methanolic sodium methoxide in an undivided cell.
When introduced in the 1950s, benzathine penicillin G (BPG) was shown to be effective in eradicating group A beta-hemolytic streptococcus (GAS) for at least 3 weeks after administration. Several studies since the 1990s suggest that at 3-4 weeks serum penicillin G levels are less than adequate (below MIC(90) of 0.016 µg/ml). We studied these levels for 4 weeks after the recommended dose of BPG in military recruits, for whom it is used as prophylaxis against GAS. The 329 subjects (mean age 20 years) each received 1.2 million units BPG IM and gave sera 1 day post injection and twice more at staggered time points over 4 weeks. Serum penicillin G levels were measured by liquid chromatography/tandem mass spectometry. The half-life of serum penicillin G was 4.1 days. By day 11, mean levels were <0.02 µg/ml, and by day 15<0.01 µg/ml. Levels in more than 50% of the subjects were below 0.02 µg/ml on day 9, and <.01 µg/ml on day 16. There was no demonstrable effect of subject body-surface area nor of the four different lots of BPG used. These data indicate that in healthy young adults serum penicillin G levels become less than protective <2½ weeks after injection of 1.2 million units of BPG. The findings require serious consideration in future medical and public health recommendations for treatment and prophylaxis of GAS upper respiratory tract infections.
There are two effective methods now available for the prevention of rheumatic fever or its recurrences. Prompt and vigorous treatment of the initiating streptococcal infection with one of the antibiotic drugs may prevent the complication of rheumatic fever, or the maintenance of continuous antibiotic therapy in the rheumatic subject may prevent recurrences by affording protection against infection by group A streptococci.1 Penicillin promises to be the antibiotic of choice for the prevention of rheumatic fever by either of the above methods for several reasons: its action is bactericidal rather than bacteriostatic2; the streptococcal pharyngeal carrier state is eliminated most effectively by treatment with adequate doses of penicillin3; strains of group A streptococci resistant to penicillin have not emerged, despite the widespread use of this drug4; and fatal or serious toxic reactions are relatively rare.
The problem of employing penicillin as a prophylactic agent is largely a
- J L Szabo
- C D Edwards
- W F Bruce
Szabo, J. L., Edwards, C D., and Bruce, W. F. (1951). Antfbiot. and
Chemother.. 1, 499.
- W Elias
- A H Price
- H J Merrion
Elias, W., Price, A. H, and Merrion, H. J. (1951). Andbiot. and Chemother., 1, 491.
- O 'brien
- J F Smith
O'Brien, J. F., and Smith, C. A. (1952). Amet. J. Syph.. 36, 519.
- R H More
- G C Mcmillan
- G L Duff
More, R. H., McMillan, G. C., and Duff, G. L. (1946). Amer. J. Path.,
22, 703.
Bact (From the Department of Bacteriology and the Wright- Fleming Institute of Microbiology, St. Mary's Hospital Medical School
- C R Knappett
- M D Dip
C. R. KNAPPETT, M.D., Dip.Bact
(From the Department of Bacteriology and the Wright-
Fleming Institute of Microbiology, St. Mary's Hospital
Medical School, London, W.2)
- G M Bull
- A M Joekes
- K G Lowe
Bull, G. M., Joekes, A. M., and Lowe, K. G. (1949). Lancet, 2, 229.
- G H Stollerman
Stollerman, G. H., and Rasoff, J H. (1952). J. Amer. med. Ass., 150, 1571.
- Moore H Jessop
- W J E O 'donovan
- D K Barry
- A P Quinn
- B Drury
Moore. H., Jessop, W. J. E., O'Donovan, D. K., Barry, A. P., Quinn, B.,
and Drury, M. I. (1951). British Medical Journal, 1, 841.
- H Selye
Selye, H. (1951). Annual Report on Stress. Montreal.